IN8bio (NASDAQ:INAB) Posts Quarterly Earnings Results, Beats Expectations By $0.35 EPS

IN8bio (NASDAQ:INAB) posted its quarterly earnings results on Thursday. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.35, Zacks reports.

IN8bio Trading Down 6.6%

NASDAQ INAB traded down $0.11 during trading hours on Friday, hitting $1.55. 89,551 shares of the company were exchanged, compared to its average volume of 68,833. The stock has a market cap of $7.04 million, a PE ratio of -0.28 and a beta of 0.02. IN8bio has a 52 week low of $1.53 and a 52 week high of $12.53. The stock has a 50-day moving average price of $2.09 and a 200 day moving average price of $2.73. The company has a quick ratio of 7.03, a current ratio of 7.03 and a debt-to-equity ratio of 0.01.

Analyst Ratings Changes

Several analysts have commented on the stock. Zacks Research upgraded shares of IN8bio from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 14th. Mizuho set a $4.00 target price on IN8bio in a report on Monday, October 13th. Wall Street Zen upgraded IN8bio from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of IN8bio in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $92.00.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.